Influence of total nucleated cell dose on the efficacy of cord blood transplantation

LIU Sha; HAO Wen-Ge; HUANG Yong-Lan; SUN Xin

PDF(977 KB)

Chinese Journal of Contemporary Pediatrics ›› 2010, Vol. 12 ›› Issue (07) : 551-556.

CLINICAL RESEARCH

Influence of total nucleated cell dose on the efficacy of cord blood transplantation

LIU Sha, HAO Wen-Ge, HUANG Yong-Lan, SUN Xin

Author information +

History +

Abstract

OBJECTIVE: To study the influence of cord blood total nucleated cell (TNC) dose on the efficacy of cord blood transplantation in children. METHODS: Thirty-four children with hematological disease received cord blood transplantation. They were assigned to 3 groups according to the infused TNC dose: TNC>10×107/kg (n=7), 10×107/kg>TNC≥7×107/kg (n=9) and TNC<7×107/kg (n=18). The rates of graft and rejection of hematopoietic stem cells and the efficacy of transplantation were examined in the three groups. RESULTS: All 7 children in the group infused with TNC >10×107/kg got a long-term stable engraftment. The median time of absolute neutrophil count >0.5×109/L was 14.8 days (range 12-20 days) and platelets >50×109/L was 52.3 days (range 26-86 days). They survived in a disease-free state. Of the 9 children in the group infused with TNC between 10×107/kg and 7×107/kg, 7 got engraftment. The median time of absolute neutrophil count >0.5×109/L was 16.4 days (range 11-30 days) and platelets >50×109/L was 63.7 days (range 34-140 days). Four children got a long-term stable engraftment and survived in a disease-free state. Two children with beta-thalassemia major had secondary rejection after engraftment and autologous hematopoitic recovery. One child died after engraftment and one child died in the early period after transplantation. Of the 18 children in the group infused with TNC <7×107/kg, 16 children got engraftment. The median time of absolute neutrophil count >0.5×109/L was 19.5 days (range 10-29 days) and platelets >50×109/L was 70.1 days (range 41-116 days). Eight children had a long-term stable engraftment and survived in a disease-free state. Two children with beta-thalassemia major had secondary rejection after engraftment and autologous hematopoitic recovery. Six children died after engraftment. Two children had graft failure. CONCLUSIONS: TNC dose is an important influencing factor for hematopoietic stem cell engraftment in cord blood transplantation. An increased TNC dose may improve the success of cord blood transplantation.［Chin J Contemp Pediatr, 2010, 12 (7):551-556］

Key words

Cord blood transplantation / Hematopoietic stem cell / Engraftment / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LIU Sha, HAO Wen-Ge, HUANG Yong-Lan, SUN Xin. Influence of total nucleated cell dose on the efficacy of cord blood transplantation[J]. Chinese Journal of Contemporary Pediatrics. 2010, 12(07): 551-556

References

［1］顾龙君, 孙桂香. 小儿急性淋巴细胞白血病诊疗建议（第二次修订草案）［J］.中华儿科杂志,1999,37(5):305-307.
［2］Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia with bone marrow transplantation［J］. Bone Marrow Transplant, 2001, 28:S11-S13.
［3］Rocha V, Cornish J, Sievers EL, Filipovich A, Locatelli F, Peters C, et al. Comparison of outcomes of unrelated bone marrow and unbilical cord blood transplants in children with acute leukemia［J］. Blood, 2001, 97(10):2962-2971.
［4］廖灿, 刘斌, 黄以宁, 许遵鹏, 辜少玲, 吴韶清，等. 54例非亲缘脐血造血干细胞移植回顾分析［J］. 中国实验血液学杂志, 2005, 13(2): 240-244.
［5］Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al.Outcome of cord-blood transplantation from related and unrelated donors: Eurocord Transplant Group and the European Blood and Marrow Transplantation Group［J］. N Engl J Med, 1997, 337(6):373-381.
［6］Kurtzberg J, Prasad VK, Carter SL, Wagner JE, Baxter-Lowe LA, Wall D, et al. Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies［J］. Blood, 2008, 112(10):4318-4327.
［7］Gluckman E. Hematopoietic stem-cell transplants using umbilical-cord blood［J］. N Engl J Med, 2001, 344(24):1860-1861.
［8］Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival［J］. Blood, 2002, 100(5): 1611-1618.
［9］Styczynski J, Cheung YK, Garvin J, Savage DG, Billote GB, Harrison L, et al. Outcomes of unrelated cord blood transplantation in pediatric recipients ［J］. Bone Marrow Transplant, 2004, 34(2), 129-136.
［10］Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, et al. Transplantation of ex vivo expanded cord blood［J］. Biol Blood Marrow Transplant, 2002,8(7):368-376.
［11］廖灿，杨昕，许遵鹏，陈劲松，黄以宁，刘斌，等. 多份脐血移植13 例回顾性分析［J］. 中国实验血液学杂志, 2004, 12 (3) :274 -277
［12］Goussetis E, Peristeri J, Kitra V, Kattamis A, Petropoulos D, Papassotiriou I, et al. Combined umbilical cord blood and bone marrow transplantation in the treatment of beta-thalassemia major［J］. Pediatr Hematol Oncol, 2000, 17(4):307-314.
［13］Magro E, Regidor C, Cabrera R, Sanjuán I, Forés R, García-Marco J, et al. Early hematopoietic recovery after single unit unrelated cord blood transplantation in adults supported by co-infusion of mobilized stem cells from a third party donor［J］. Haematologica, 2006, 91(5):640-648.
［14］Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA matching, cell dose and other graft-and transplantationrelated factors［J］. Br J Haematol, 2009, 147(2):262-274.